SCHEDULE 13D: Quoin Pharmaceuticals CEO Dr. Michael Myers Boosts Stake to 6.9% Through Recent Share and Warrant Purchases

Quoin Pharmaceuticals Ltd.'s CEO and Chairman, Dr. Michael Myers, has increased his beneficial ownership in the company to 6.9% through recent purchases in a public offering and the grant of new stock options, signaling continued investment in the company's future.

Summary

• Dr. Michael Myers, CEO and Chairman of Quoin Pharmaceuticals Ltd., beneficially owns 622,573 Ordinary Shares (represented by American Depositary Shares or ADSs), which constitutes 6.9% of the company's outstanding shares as of December 23, 2024.
• This ownership includes 602,808 ADSs held directly and 19,765 ADSs exercisable from outstanding options within 60 days.
• The reported beneficial ownership excludes 604,946 ADSs from options not yet exercisable and 1,111,112 shares from Series F and G warrants due to a 4.99% ownership blocker.
• On December 23, 2024, Dr. Myers purchased 555,556 ADSs, along with an equal number of Series F and Series G Warrants, in the Issuer's public offering at a combined price of $0.45 per ADS.
• Additionally, on December 9, 2024, Dr. Myers was granted an option to purchase 536,603 ADSs at an exercise price of $0.78, which will vest in annual installments through December 2028.
• The shares were acquired for investment purposes, and Dr. Myers, in his capacity as CEO and Chairman, will continue to consider actions advantageous to the Issuer, including potential corporate transactions.

Sentiment

Score: 7

Explanation: The filing indicates strong insider confidence with the CEO increasing his beneficial ownership and participating in a public offering. This is generally a positive signal for investors. However, the very low recent share price (implied by the $0.45 offering price and $0.78 new option price compared to older $210 options) and the 4.99% ownership blocker on warrants introduce some complexities.

Positives

• Increased beneficial ownership by the CEO and Chairman, Dr. Michael Myers, to 6.9% signals strong insider confidence and alignment with shareholder interests.
• The CEO's direct participation in the company's public offering demonstrates a personal financial commitment to the company's capital raising efforts.
• The acquisition of additional options and warrants provides long-term incentives for the CEO, linking his compensation to the company's future performance.

Negatives

• The 4.99% ownership blocker on the Series F and G Warrants limits the immediate exercisability of a significant portion of Dr. Myers' potential ownership, potentially impacting his ability to fully capitalize on the warrants in the short term.
• The exercise price of the oldest options ($210) is significantly higher than the recent public offering price ($0.45) and the exercise price of the newest options ($0.78), indicating a substantial decline in the company's share price since the initial grant.

Risks

• The 4.99% ownership blocker on Series F and G Warrants prevents the immediate exercise of a large number of shares (1,111,112 ADSs), potentially limiting the Reporting Person's ability to increase his stake beyond this threshold without further regulatory considerations or changes.
• The lack of an expected trading market for the Series F and G Warrants could limit their liquidity and valuation outside of direct exercise.
• The vesting schedules for options mean a significant portion of potential beneficial ownership is not immediately available, tying the realization of these shares to future performance and continued employment.

Future Outlook

Dr. Michael Myers, as CEO and Chairman, intends to regularly consider potential actions and transactions advantageous to Quoin Pharmaceuticals Ltd., including possible mergers, acquisitions, reorganizations, or other material changes to the business, corporate structure, management, policies, or regulatory obligations. He may also acquire additional securities through option exercises, vesting, new grants, or open market purchases if market conditions are favorable.

Management Comments

• "The Ordinary Shares reported herein as beneficially owned by the Reporting Person were acquired by the Reporting Person for investment purposes."
• "As the Chief Executive Officer and Chairman of the Board of Directors of the Issuer, the Reporting Person will regularly consider potential actions and transactions that may be advantageous to the Issuer, including possible mergers, acquisitions, reorganizations or other material changes in the business, corporate structure, management, policies, governing instruments, securities or regulatory or reporting obligations of the Issuer."
• "The vesting of the unvested options described above will increase the Reporting Person's beneficial ownership of Ordinary Shares."

Industry Context

This Schedule 13D filing indicates a significant insider stake increase by the CEO of Quoin Pharmaceuticals, a common occurrence in smaller biotechnology or pharmaceutical companies where management often holds substantial equity. Such filings are closely watched by investors for signals of management confidence, especially in companies that may be undergoing strategic shifts or capital raises, as Quoin Pharmaceuticals appears to be with its recent public offering. The presence of warrants and options with varying exercise prices and vesting schedules is typical for executive compensation in the biotech sector, aiming to align long-term interests.

Comparison to Industry Standards

• The CEO's beneficial ownership of 6.9% is a substantial insider stake, often considered a positive signal of alignment with shareholder interests, especially for a small-cap pharmaceutical company. This level of insider ownership can be higher than in large, established pharmaceutical companies where ownership is more diffused.
• The structure of executive compensation, including stock options and warrants with vesting schedules, is standard practice across the pharmaceutical and biotechnology industries, designed to incentivize long-term performance and retention.
• The inclusion of a 4.99% ownership blocker in the warrants is a common anti-takeover or regulatory compliance mechanism, particularly in companies that might be sensitive to rapid changes in control or to avoid certain reporting thresholds.

Legal Proceedings

• The Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the past five years.
• The Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the past five years.

Related Party Transactions

• Dr. Michael Myers, as the Chief Executive Officer and Chairman of Quoin Pharmaceuticals Ltd., purchased 555,556 ADSs along with Series F and Series G Warrants in the Issuer's public offering on December 23, 2024.
• On December 9, 2024, the Issuer granted Dr. Myers an option to purchase 536,603 ADSs.

Stakeholder Impact

• Shareholders: The increased insider ownership by the CEO may be viewed positively, signaling confidence and alignment of interests. However, the dilution from the public offering and the low offering price could be a concern for existing shareholders.
• Employees: The CEO's continued investment and long-term incentives through options may contribute to stability and strategic direction.
• Creditors: No direct impact mentioned, but the capital raise (implied by the public offering) could improve the company's financial position.

Next Steps

• The vesting of unvested options will continue to increase the Reporting Person's beneficial ownership of Ordinary Shares.
• Dr. Myers may acquire additional securities through the exercise of currently held options or warrants, the vesting of options, the grant of additional options, or open market purchases.
• As CEO and Chairman, Dr. Myers will regularly consider potential strategic actions for the Issuer, including mergers, acquisitions, or reorganizations.

Key Dates

Recommendation

Keywords

Quoin Pharmaceuticals, Michael Myers, Schedule 13D, beneficial ownership, stock options, warrants, Series F Warrants, Series G Warrants, public offering, insider buying, corporate governance, equity plans, SEC filing